QIBA FDG-PET/CT Tech Ctte Update Call
18 January 2013 at 9 AM CT (GMT-6)

Call Summary

In attendance:

Paul E. Kinahan, PhD (co-chair)
Ling X. Shao, PhD (co-chair)
Onikepe Adegbola, MD, PhD
Andrew Buckler, MS
Paul Christian
Barbara Croft, PhD
Edward Eikman, MD
Kirk Frey, MD, PhD
Howard Higley, PhD

Martin Lodge, PhD
Lawrence MacDonald, PhD
Neru Munshi, PhD
Eric Perlman, MD
Daniel C. Sullivan, MD
John Sunderland, PhD
Valerie Treyer, PhD
Scott Wollenweber, PhD

John Wolodzko, PhD
Jeffrey T. Yap, PhD
Brian Zimmerman, PhD
RSNA
Joe Koudelik
Julie Lisiecki

Agenda, 1/18 - provided by co-chairs
1. Profile update (should be released by then) - RSNA
2. Dr. Kirk Frey – introduction/ discussion regarding the potential of writing a QIBA Profile for brain PET imaging
3. Project update from Dr. Hoekstra or designate
4. Recruitment for Dr. Wahl’s multi-reader study (attachments were distributed)
5. FDA qualification update – Dr. Howard Higley
6. QIBA updates – Dr. Sullivan / Mr. Buckler

Discussion:

• The Profile, *FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy. v1.02, Version for Public Comment, January 11, 2013*, is out for the first phase of Public Comment.
  - Tech committee members are encouraged to forward the Profile to colleagues for additional Public Comment feedback, however, this is still a preliminary phase before the Profile is broadly distributed during the Profile Implementation Phase
  - Dr. Wolodzko suggested a few organizations to add to the Profile Implementation distribution list: AAPM, ACRIN, ACR, SNM, UPICIT, NEMA
  - Requests to colleagues should include a brief note of introduction to the project and its purpose

• Mr. O’Donnell will instruct the group further about subsequent Profile Review phases for on the 1/25 call

• Dr. Frey joined the group to discuss the possibility of new Profile efforts for the group in various areas of brain imaging
  - Dr. Frey suggested that there would be significant challenges in pursuing a Profile with FDG-PET brain imaging as a potential biomarker in clinical investigations, but did suggest a multi-site effort, if to be pursued
  - The [Alzheimer’s Disease Neuroimaging Initiative](https://www.adni-info.org) (ADNI) has had long-running financial support from NIH and Pharma, and this may be an avenue for consideration
    - Currently, limited published longitudinal datasets exist for brain imaging, which would make this effort difficult
    - The possibility exists to assess data analysis techniques and check them against the ADNI database
  - Dr. Kinahan suggested working toward a validated assay aspect – looking to define size, reproducibility, and reliability as a starting point
  - Dr. Frey suggested that the tech ctte invite Dr. Koeppe for further discussion, particularly on the topic of the Hoffman phantom for iterative reconstruction and analysis methods
    - Dr. Kinahan to follow up with Dr. Koeppe and invite him to the next call
  - The best test method is to supply a common dataset and test outcomes

• Dr. Yap reminded the group about Dr. Wahl’s multi-reader study and asked that members return the survey forms

• Dr. Higley gave an update on the FDA qualification efforts and noted that there is a rolling series of submissions as new evidence is developed
  - The FDA is particularly interested in the ACRIN test/ retest data
  - It is possible that Dr. Wahl’s second analysis may be included , as well as data from Drs. Hoekstra and Yap’s collaborative projects
  - The next FDA briefing document is expected to be forwarded during Q1 of 2013; this will be for educational purposes; no formal in-person meeting is expected to result from this update
Action items for 1/25 – as assigned by the co-chairs:

1. Dr. Kinahan to follow up with Drs. Hoekstra and Koeppre re: presentations for 1/25
2. Project update from Dr. Hoekstra or designate pending availability
3. Continued recruitment for Dr. Wahl’s multi-reader study (attachments were distributed)
4. Review of QIBA FDG-PET Technical Ctte roster by all members for inclusion in Profile Appendix
5. Tech Committee members to provide comments on work product for review form (wiki)
6. RSNA staff to remind Mr. O’Donnell about his presentation (Review of Profile stages)

Next call: January 25, 2013 at 9 am CT.